



**Supplementary Figure 3**

**Supplementary Figure 3. Clinical presentation and predictors of COVID-19-specific re-hospitalization in lymphoma patients.** a) Inclusion criteria for cohorts used for analysis in Figure 3 and Supplementary Figure 3. b) Serial CT images for Patients E, H, M (from Table 2) over three separate time points from initial diagnosis. Patient E with waxing and waning ground glass opacities and patchy infiltrates, later characterized by increasing consolidation. Patient H with waxing and waning ground glass opacities with eventual clearing. Patient M with waxing and waning ground glass opacities with coarsening over time. c) Univariate analysis of clinical risk factors predicting re-hospitalization attributable to COVID-19 infection in patients with lymphoma and prior hospitalization attributable to COVID-19. Statistically significant risk factors highlighted in red. d) Laboratory markers in patients with lymphoma who either died from acute COVID-19 infection, survived acute infection and were not re-admitted to the hospital, or survived acute infection and were re-admitted to the hospital for COVID-19 infection. \*\* $p < 0.01$ . \*\*\* $p < 0.001$ . \*\*\*\* $p < 0.0001$ .